期刊文献+

重组PACAP衍生物RMBYLL的高效制备及其体外生物学效应 被引量:2

Highly Efficient Preparation of Recombinant PACAP Derivate RMBYLL and Its Biological Effects in Vitro
原文传递
导出
摘要 为了利用基因工程技术高效制备具有治疗Ⅱ型糖尿病功能的垂体腺苷酸环化酶激活肽(PACAP)衍生物RMBYLL,并在体外研究其生物学效应,采用基因重组技术表达重组肽RMBYLL,纯化、制备并鉴定重组肽RMBYLL后,利用特定细胞系和Western-blot等技术,检测RMBYLL对VPAC1、VPAC2和PAC1受体的选择性和激动活性,以及重组肽RMBYLL对胰岛素受体介导的信号传导最终效应物—葡萄糖转运蛋白4(GLUT4)表达的影响。实验结果表明:利用重组肽技术制备的RMBYLL的M_r为3.901k,纯度大于95%,其产率为18.7 mg/(L发酵产物);制备的RMBYLL可与VPAC2受体特异结合并显著促进VPAC2-CHO细胞cAMP的产生,其受体半激活浓度(EC_(50))为0.90 nmol/L,目的肽RMBYLL可显著增强3T3-L1脂肪细胞GLUT4的表达,阳性实验组是对照组的1.91倍。由此表明,利用本研究确立的表达、纯化策略可实现高活性RMBYLL的高效制备,应用前期构建的含有特定受体的CHO细胞和3T3-L1脂肪细胞模型,可方便有效地进行相关药物肽的体外生物学效应研究。 In order to efficiently prepare the pituitary adenylate cyclase activating polypeptide (PACAP) derivate RMBYLL against type Ⅱ diabetes by genetic engineering technique and to study its biological effects in vitro, genetic recombination technique was used to express the recombinant RMBYLL. After purifying, preparation and identifing recombinant peptide RMBYLL, using selective cells with Western-blot and other techniques ,the selectivity and potency of RMBYLL at human VPAC1 ,VPAC2 and PAC1 receptor were assayed. And the effect of RMBYLL on the expression of glucose transporter 4 ( GLUT4 ) , the last effector protein of insulin signaling, was determined. The experimental results showed that the molecular weight of RMBYLL was 3. 901k,its purity was greater than 95% and its yield was 18.7 mg/( L fermentation product). Prepared RMBYLL could specifically act on VPAC2 with a half-maximal stimulatory concentration ( EC50 ) of 0.90 nmol/L and significantly enhanced cAMP accumulation in CHO cells. RMBYLL may significantly induce GLUT4 expression in differentiated 3T3-L1 adipocytes. GLUT4 protein was increased 0.91-fold in the treated cells with RMBYLL. These results showed that the strategy established for expression and purification by this study can achieve the effi- cient preparation of recombinant peptide with high activity. The biological effects in vitro could be conveniently and accurately investigated with CHO cells and 3T3-L1 adipocytes that were constructed in previous study.
出处 《药物生物技术》 CAS CSCD 2011年第5期387-391,共5页 Pharmaceutical Biotechnology
基金 教育部科学技术研究重点项目(210260) 广东省自然科学基金项目(9451063201002336) 广东省教育部产学研结合项目(2010B090400544) 中国博士后科学基金项目(20090460785) 中央高校基本科研业务费专项资金资助项目(21610426) "211工程"Ⅲ期项目
关键词 基因重组 垂体腺苷酸激活肽衍生物 血管活性肠肽/垂体腺苷酸环化酶活化肽受体2 生物学效应 Genetic recombination, PACAP derivate,VPAC2 receptor, Biological effects
  • 相关文献

参考文献3

二级参考文献15

  • 1余榕捷,高媛,洪岸.提高Xa因子酶切效率的策略[J].中国生物工程杂志,2004,24(12):84-88. 被引量:4
  • 2Ghzili H, Grumolato L, Thou? nnon E, et al. Role of PACAP in the physiology and pathology of the sympathoadrenal system. Front Neuroendocrinol, 2008, 29 ( 1 ) :128 ~ 141
  • 3Winzell M S, Ahren B. Role of VIP and PACAP in islet function. Peptides, 2007, 28(9):1805- 1813
  • 4Pan C Q, Li F, Tom I, et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J Pharmacol Exp Ther, 2007, 320 ( 2 ) : 900-906
  • 5Yung S L, Cruz F D, Hamren S, et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclaseactivating peptide. J Biol Chem, 2003, 278 (12) : 10273 - 10281
  • 6Tsutsumi M, Claus T H, Liang Y, et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal, a potential therapy for type 2 diabetes. Diabetes, 2002, 51 (5) : 1453 - 1460
  • 7Yu R J, Xie Q L, Dai Y, et al. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides, 2006, 27 (6) :1359 -1366
  • 8Wilson R J, Cummings K J. Pituitary adenylate cyclase-activating polypeptide is vital for neonatal survival and the neuronal control of breathing. Respir Physiol Neurobiol, 2008, 164(1-2) : 168 -178
  • 9Yu R J, TAM N L, Gao Y, et al. A novel recombinant,VPAC2-seleetive agonist enhancing insulin release and glucose disposal. Acta Pharmacol Sin, 2007, 28 (4):526 - 533
  • 10Moreno D, Gourlet P, De Neef P, et al. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides, 2000, 21 (10) :1543 - 1549

共引文献8

同被引文献30

  • 1陆融,王卓,姚智.小分子多肽抗肿瘤作用的研究进展[J].天津医科大学学报,2005,11(3):499-502. 被引量:10
  • 2王丽静,张尉,刘小莺,黄培基,刘礼斌.地塞米松诱导3T3-L1脂肪细胞胰岛素抵抗模型的建立[J].福建医科大学学报,2007,41(3):282-284. 被引量:29
  • 3杨桂枝,高小平,晏菊芳,欧可群,赵佳.罗格列酮改善胰岛素抵抗细胞摄取葡萄糖的途径研究[J].四川大学学报(医学版),2007,38(5):816-818. 被引量:5
  • 4Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword [ J ]. Nat Rev Imrnunol,2003,3 (9) :745.
  • 5Carswell EA,Old LJ,Kassel RL,et al. An endotoxin-induced serum factor that causes necrosis of tumors [ J ]. Proc Natl Acad Sci U S A,1975,72(9) :3666.
  • 6Shalaby MR, Aggarwal BB, Rinderknecht E, et al. Activation of human polymorphonuclear neutrophil functions by interferon- gamma and tumor necrosis factors [ J l. J Immunol, 1985,135 ( 3 ) :2069.
  • 7Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF- alpha in cancer[ J ]. Curr Opin Immunol, 1998,10 (5) :573.
  • 8Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes [ J ]. Cell,2003, 114(2) :181.
  • 9Wang L,Du F,Wang X. TNF-alpha induces two distinct caspase- 8 activation pathways[ J]. Cell ,2008,133(4) :693.
  • 10Kim JJ, Lee SB, Park JK, et al. TNF-alpha-induced ROS produc- tion triggering apoptosis is directly linked to Romol and Bcl-X (L) [J]. Cell Death Differ,2010 ,17 ( 9 ) :1420.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部